Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cav3.2 is a subtype of T-type voltage-gated calcium channels, encoded by the CACNA1H gene. It is widely expressed throughout the central nervous system and peripheral tissues, playing critical roles in neuronal excitability, pacemaking activity, and pain signaling. Dysfunction or altered expression/activity of Cav3.2 has been linked to several disorders, including neuropathic pain and absence epilepsy, making it a promising target for analgesics development.
Selective antagonists block ion flow via distinct structural mechanisms
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-type voltage-gated calcium channel 3.2 (Cav3.2).